Alpha 2.0
Login Register
» Authors » Martin Hibberd

Martin Hibberd

Explore the profile of Martin Hibberd including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 39
Citations 939
Followers 0
Related Specialties
Infectious Diseases
Genetics
Microbiology
Top 10 Co-Authors
Chris Smith
Takeshi Arashiro
Koya Ariyoshi
Ashley Stucky
Yuzo Arima
Motoi Suzuki
Yusuke Nishida
Akihiro Ueda
Hideaki Oka
Hideaki Kato
Published In
PLoS One
Vaccine
J Infect Dis
Emerg Infect Dis
J Immunol
Affiliations
Soon will be listed here.
Recent Articles
1.
Sociobehavioural factors associated with SARS-CoV-2 infection and COVID-19 vaccine effectiveness against medically attended, symptomatic SARS-CoV-2 infection in the Philippines: a prospective case-control study (FASCINATE-P study)
Arashiro T, Berba R, Calayo J, Kris M, Garcia R, Suzuki S, et al.
Western Pac Surveill Response J . 2025 Mar; 16(1):1-12. PMID: 40034498
Objective: We examined sociobehavioural factors associated with SARS-CoV-2 infection and estimated COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection in the Philippines. Such studies are limited in low- and middle-income countries,...
2.
Factors associated with COVID-19 in-hospital death and COVID-19 vaccine effectiveness against COVID-19 hospitalization in the Philippines during pre-omicron and omicron period: A case-control study (MOTIVATE-P study)
Arashiro T, Solante R, Sayo A, Garcia R, Kris M, Suzuki S, et al.
Epidemiol Infect . 2024 Dec; 153():e18. PMID: 39703003
COVID-19 vaccine effectiveness (VE) studies are limited in low- and middle-income countries. A case-control study was conducted among COVID-19 and other pneumonia patients admitted to a hospital in the Philippines...
3.
Phylogenetic inference of pneumococcal transmission from cross-sectional data, a pilot study
Hackman J, Sheppard C, Phelan J, Jones-Warner W, Sobkowiak B, Shah S, et al.
Wellcome Open Res . 2024 Apr; 8:427. PMID: 38638914
Inference on pneumococcal transmission has mostly relied on longitudinal studies which are costly and resource intensive. Therefore, we conducted a pilot study to test the ability to infer who infected...
4.
Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
Paton N, Gurumurthy M, Lu Q, Leek F, Kwan P, Koh H, et al.
J Infect Dis . 2024 Mar; 230(3):590-597. PMID: 38527849
Background: Interleukin 4 (IL-4), increased in tuberculosis infection, may impair bacterial killing. Blocking IL-4 confers benefit in animal models. We evaluated safety and efficacy of pascolizumab (humanized anti-IL-4 monoclonal antibody)...
5.
COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study)
Arashiro T, Miwa M, Nakagawa H, Takamatsu J, Oba K, Fujimi S, et al.
Vaccine . 2023 Dec; 42(3):677-688. PMID: 38114409
Introduction: Since the SARS-CoV-2 Omicron variant became dominant, assessing COVID-19 vaccine effectiveness (VE) against severe disease using hospitalization as an outcome became more challenging due to incidental infections via admission...
6.
Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan
Arashiro T, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, et al.
Vaccine . 2023 Oct; 41(47):6969-6979. PMID: 37839947
Background: Repeated emergence of variants with immune escape capacity and waning immunity from vaccination are major concerns for COVID-19. We examined whether the surge in Omicron subvariant BA.5 cases was...
7.
Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
Arashiro T, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, et al.
Open Forum Infect Dis . 2023 Jun; 10(6):ofad240. PMID: 37351451
In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was...
8.
MUC5AC Genetic Variation Is Associated With Tuberculous Meningitis Cerebral Spinal Fluid Cytokine Responses and Mortality
Sabo M, Thuong N, Chang X, Ardiansyah E, Tram T, Hai H, et al.
J Infect Dis . 2023 Feb; 228(3):343-352. PMID: 36823694
Background: The purpose of this study was to assess if single nucleotide polymorphisms (SNPs) in lung mucins MUC5B and MUC5AC are associated with Mycobacterium tuberculosis outcomes. Methods: Independent SNPs in...
9.
Letter to the editor: Importance of considering high-risk behaviours in COVID-19 vaccine effectiveness estimates with observational studies
Arashiro T, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, et al.
Euro Surveill . 2023 Jan; 28(4). PMID: 36700869
No abstract available.
10.
Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control...
Arashiro T, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, et al.
Clin Infect Dis . 2022 Aug; 76(3):e108-e115. PMID: 35918782
Background: Although several coronavirus disease 2019 (COVID-19) vaccines initially showed high efficacy, there have been concerns because of waning immunity and the emergence of variants with immune escape capacity. Methods:...